Natriuretic peptide receptor type-A (NPR-A)

Natriuretic peptide receptor type-A (NPR-A), also known as guanylate cyclase A (GC-A), is a primary transmembrane receptor responsible for mediating the physiological effects of atrial and B-type natriuretic peptides (ANP and BNP) [1, 2]. Upon binding these ligands, NPR-A activates its intracellular guanylyl cyclase domain to produce cyclic guanosine monophosphate (cGMP), which serves as a critical second messenger for vasodilation, natriuresis, and diuresis [6, 8]. This signaling pathway is essential for maintaining blood pressure and fluid homeostasis, while also providing direct cardioprotective effects by inhibiting pathological cardiac hypertrophy and fibrosis [11, 13]. In disease states such as heart failure and hypertension, the NPR-A system is often insufficient or dysregulated, making it a key therapeutic target [7, 10]. Drugs like nesiritide}

Other names

Guanylate cyclase AGC-AAtrial natriuretic peptide receptor 1NPR1Atrial natriuretic peptide receptor type AANPR-AParticulate guanylate cyclase A

Agonism of the receptor's intrinsic guanylyl cyclase activity to increase intracellular cGMP levels.